Research Article
Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC
Table 1
Summary of WDTC patients harboring dedifferentiated phenotype in the FUSCC cohort.
| | Variables | FUSCC () | | N | % |
| | Age (years), mean ± SD (range) | 53.0 ± 15.3 (15–85) | | Gender | | | | Male | 29 | 46.1% | | Female | 34 | 53.9% | | Maximum size (cm), mean ± SD (range) | 3.39 ± 2.3 (0.3–8.6) | | ETE | | | | Yes | 15 | 23.8% | | No | 48 | 76.2% | | Histological subtypes of WDTC | | | | PTC | 54 | 85.7% | | Classic PTC | 46 | 73.0% | | Follicular PTC | 2 | 3.2% | | Solid PTC | 1 | 1.6% | | PTMC | 5 | 7.9% | | FTC | 9 | 14.3% | | Dedifferentiated site | | | | Thyroid | 40 | 63.5% | | Lymph node | 17 | 27.0% | | Distant site | 1 | 1.6% | | Thyroid and lymph node | 4 | 6.3% | | Thyroid and distant site | 1 | 1.6% | | Dedifferentiated components | | | | PDTC | 50 | 79.4% | | ATC | 13 | 20.6% | | LNM | | | | N0 | 22 | 34.9% | | N1 | 41 | 65.1% | | DM | | | | M0 | 47 | 74.6% | | M1 | 16 | 25.4% | | TNM stage (the 8th edition) | | | | I/II | 41 | 65.1% | | III/IV | 22 | 34.9% | | Adjuvant therapy | | | | Yes | 15 | 23.8% | | RAI | 8 | 12.7% | | Radiotherapy | 3 | 4.8% | | Chemotherapy | 1 | 1.6% | | Chemoradiotherapy | 3 | 5.3% | | No | 48 | 76.2% |
|
|
WDTC: well-differentiated thyroid cancer; FUSCC: Fudan University Shanghai Cancer Center; SD: standard deviation; ETE: extrathyroidal extension; PTC: papillary thyroid cancer; PTMC: papillary thyroid microcarcinoma; FTC: follicular thyroid cancer; PDTC: poorly differentiated thyroid cancer; ATC: anaplastic thyroid cancer; LNM: lymph node metastasis; DM: distant metastasis; TNM: tumor-node-metastasis; RAI: radioactive iodine.
|
